Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis YoY Growth in the U.S.: 3.0% in Q3 2026, down 10.0 pts from a year earlier. That is the lowest of the 16 quarters on record here.
Latest, Q3 2026
3.0%
Period ended Sep 30, 2026
Change on a year earlier
-10.0 pts
13.0% in Q3 2025
History
16 quarters
Since Q3 2019
Sources
16
Documents cited below
Where the Q3 2026 figure comes from
“|| Lutathera | Oncology | GEP-NETs gastroenteropancreatic neuroendocrine tumors | 156 | 3 | 63 | 3 | 6 | 219 | 3 | 3”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), quarterly Q3 2019–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lutathera-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.